Abingworth llp - by affiliate investment history in Proteon therapeutics inc

Filed on 2017-06-21 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0001171843-17-003741.txt Sec File: edgar/data/1397144/0001171843-17-003741-index.htm

2017-06-20 Abingworth Llp (CIK 1397144) through By Affiliate

Invested in Proteon Therapeutics Inc bought 6666 shares at $0 remaining shares owned 6666

Stock Option Right To Buy Proteon Therapeutics Inc Prto exercise price 1.30 has valueitem expiration due date 2027-06-19 underlying security shares 6666 underlying security title Common Stock 0 001 Par Value

f1 these options (the "options") were granted to tim haines ("haines"), a member of abingworth llp ("allp"). allp provides advisory services to abingworth bioventures vi, lp ("abv vi"). under an agreement between haines and allp, haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi, and must exercise the options solely upon the direction of allp.
f3 abv vi may be deemed the indirect beneficial owner of the options, and haines may be deemed the indirect beneficial owner of the options through his indirect interest in abv vi. allp disclaims beneficial ownership of the options except to the extent, if any, of its pecuniary interest therein. this report shall not be deemed an admission that allp, abv vi, haines or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f2 the options were granted on june 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) june 20, 2018 and (ii) the issuer's next annual meeting of stockholders.


Filed on 2016-06-14 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0001171843-16-010664.txt Sec File: edgar/data/1397144/0001171843-16-010664-index.htm

2016-06-09 Abingworth Llp (CIK 1397144) through By Affiliate

Invested in Proteon Therapeutics Inc bought 6666 shares at $0 remaining shares owned 6666

Stock Option Right To Buy Proteon Therapeutics Inc Prto exercise price 5.90 has valueitem expiration due date 2026-06-08 underlying security shares 6666 underlying security title Common Stock 0 001 Par Value

f1 these options (the "options") were granted to timothy haines ("haines"), a member of abingworth llp ("allp"). allp provides advisory services to abingworth bioventures vi, lp ("abv vi"). under an agreement between haines and allp, haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi, and must exercise the options solely upon the direction of allp.
f3 abv vi may be deemed the indirect beneficial owner of the options, and haines may be deemed the indirect beneficial owner of the options through his indirect interest in abv vi. allp disclaims beneficial ownership of the options except to the extent, if any, of its pecuniary interest therein. this report shall not be deemed an admission that allp, abv vi, haines or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f2 the options were granted on june 9, 2016 and the shares underlying the options will vest 100% at the earlier of (i) june 9, 2017 and (ii) the issuer's next annual meeting of stockholders.


Filed on 2015-06-03 by Abingworth Llp SEC CIK 1397144 Form 4

Accession 0000905718-15-000524.txt Sec File: edgar/data/1397144/0000905718-15-000524-index.htm

2015-06-02 Abingworth Llp (CIK 1397144) through By Affiliate

Invested in Proteon Therapeutics Inc bought 6666 shares at $0 remaining shares owned 6666

Stock Option Right To Buy Proteon Therapeutics Inc Prto exercise price 17.59 has valueitem expiration due date 2025-06-02 underlying security shares 6666 underlying security title Common Stock 0 001 Par Value

f1 these options (the "options") were granted to timothy haines ("haines"), a member of abingworth llp ("allp"). allp provides advisory services to abingworth bioventures vi, lp ("abv vi"). under an agreement between haines and allp, haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi, and must exercise the options solely upon the direction of allp.
f3 abv vi may be deemed the indirect beneficial owner of the options, and haines may be deemed the indirect beneficial owner of the options through his indirect interest in abv vi. allp disclaims beneficial ownership of the options except to the extent, if any, of its pecuniary interest therein. this report shall not be deemed an admission that allp, abv vi, haines or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f2 the options were granted on june 2, 2015 and the shares underlying the options will vest 100% at the earlier of (i) june 2, 2016 and (ii) the issuer's next annual meeting of stockholders.